But when patents held by Pronova BioPharma were upheld in court later in the day, shares rose quickly and ended with a 6% increase on the day.
Pronova BioPharma's patents don't have any bearing on how long Amarin's AMR101 remains free from direct generic competition, but it indirectly affects the drug. Pronova's patents protect Lovaza, AMR101's direct competitor that Pronova licensed to GlaxoSmithKline
The upheld patents are set to expire in March 2013 and April 2017, but there will be a generic version of Lovaza on the market before then. Pronova settled with Apotex last year, allowing the generic-drug maker to sell its copycat beginning in the first quarter of 2015. With the win in court against the other generic-drug makers, settling with Apotex doesn't look like a particularly good move for Glaxo, Pronova, or even Amarin, but that's the way things go sometimes.
Assuming AMR101 is approved in July, there's plenty of time to get the drug established before it has to face generic competition. I wouldn't be shocked if the sales took a small hit at that point; the same phenomenon happened when Merck's
Amarin is the prototypical multibagger, up more than 300% over the past two years. Fool analysts think they've found another health-care company with just as much upside. You can read about it in their new free report "Discover the Next Rule-Breaking Multibagger." Get your copy for free.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.